TECHPRECISION CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TECHPRECISION CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $34.03M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $31.59M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $31.43M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $22.28M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $15.60M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $16.01M | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $16.70M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $18.73M | Jun 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $34.03M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $31.59M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $31.43M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $22.28M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $15.60M | Aug 10, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $4.67M | Jun 28, 2018 |
| FY2018 | Dec 31, 2017 | $3.64M | Jun 28, 2018 |
| FY2018 | Sep 30, 2017 | $4.59M | Jun 28, 2018 |
| FY2018 | Jun 30, 2017 | $5.83M | Jun 28, 2018 |
| FY2018 | Mar 31, 2017 | $4.93M | Jun 28, 2018 |
| FY2018 | Dec 31, 2016 | $5.32M | Jun 28, 2018 |
| FY2018 | Sep 30, 2016 | $3.66M | Jun 28, 2018 |
| FY2018 | Jun 30, 2016 | $4.64M | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | $4.87M | Jun 29, 2017 |
| FY2017 | Dec 31, 2015 | $3.51M | Jun 29, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.33M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $4.12M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $4.90M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $3.38M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $3.46M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $3.14M | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $4.58M | Jun 11, 2020 |
| FY2018 | Mar 31, 2018 | $380.0K | Jun 28, 2018 |
| FY2018 | Dec 31, 2017 | $423.0K | Jun 28, 2018 |
| FY2018 | Sep 30, 2017 | $1.43M | Jun 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.75M) | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | ($7.04M) | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | ($979.0K) | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | ($349.8K) | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $320.6K | Aug 10, 2022 |
| FY2019 | Mar 31, 2019 | $1.10M | Jun 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.16M) | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | ($4.63M) | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | ($1.11M) | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | ($1.56M) | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $623.2K | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | ($141.3K) | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $1.84M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $967.3K | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $2.88M | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | $2.11M | Jun 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2017 | $0 | Jun 29, 2017 |
| FY2017 | Mar 31, 2016 | $0 | Jun 29, 2017 |
| FY2016 | Mar 31, 2015 | $0 | Jun 28, 2016 |
| FY2015 | Mar 31, 2014 | $0 | Jun 29, 2015 |
| FY2014 | Mar 31, 2013 | $0 | Jul 15, 2014 |
| FY2012 | Mar 31, 2012 | $266.2K | Aug 16, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.49M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $8.75M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $6.01M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $4.94M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $2.84M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $2.79M | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $2.75M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $3.01M | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $4.34M | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | $3.39M | Jun 29, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($599.0K) | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $728.0K | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $3.14M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $257.8K | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $635.9K | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $676.8K | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $531.3K | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $1.26M | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $1.73M | Jun 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.12M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $3.23M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $2.33M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $939.0K | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $546.9K | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $39.8K | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $446.7K | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $994.5K | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $787.8K | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | $17.6K | Jun 29, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $33.53M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $34.75M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $36.21M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $37.85M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $16.00M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $14.58M | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $16.05M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $14.28M | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | $15.48M | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | $12.08M | Jun 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $24.79M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $26.94M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $21.61M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $22.59M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $6.06M | Aug 10, 2022 |
| FY2014 | Mar 31, 2014 | $13.40M | Jul 15, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $8.74M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $7.80M | Jul 30, 2025 |
| FY2025 | Mar 31, 2023 | $14.59M | Jul 30, 2025 |
| FY2024 | Mar 31, 2022 | $15.26M | Sep 13, 2024 |
| FY2023 | Mar 31, 2021 | $9.94M | Jun 15, 2023 |
| FY2022 | Mar 31, 2020 | $9.47M | Aug 10, 2022 |
| FY2021 | Mar 31, 2019 | $9.71M | Jun 10, 2021 |
| FY2020 | Mar 31, 2018 | $8.01M | Jun 11, 2020 |
| FY2019 | Mar 31, 2017 | $7.97M | Jun 27, 2019 |
| FY2018 | Mar 31, 2016 | $1.73M | Jun 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($10.15M) | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | ($7.40M) | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | ($356.4K) | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $622.6K | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $972.4K | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $651.8K | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $993.3K | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | ($576.6K) | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | ($310.7K) | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | ($5.39M) | Jun 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $195.0K | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | $138.0K | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | $534.5K | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | $1.05M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | $2.13M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | $930.9K | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | $2.04M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | $2.69M | Jun 27, 2019 |
| FY2019 | Mar 31, 2017 | $3.07M | Jun 27, 2019 |
| FY2018 | Mar 31, 2016 | $1.33M | Jun 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $6.11M | Jun 15, 2023 |
| FY2022 | Mar 31, 2022 | $7.36M | Aug 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jun 11, 2020 |
| FY2018 | Mar 31, 2018 | 0 | Jun 28, 2018 |
| FY2018 | Dec 31, 2017 | 0 | Jun 28, 2018 |
| FY2018 | Sep 30, 2017 | 0 | Jun 28, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jun 11, 2020 |
| FY2018 | Mar 31, 2018 | 0 | Jun 28, 2018 |
| FY2018 | Dec 31, 2017 | 0 | Jun 28, 2018 |
| FY2018 | Sep 30, 2017 | 0 | Jun 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 9.75M | Jul 30, 2025 |
| FY2025 | Mar 31, 2024 | 8.78M | Jul 30, 2025 |
| FY2024 | Mar 31, 2023 | 8.61M | Sep 13, 2024 |
| FY2023 | Mar 31, 2022 | 8.58M | Jun 15, 2023 |
| FY2022 | Mar 31, 2021 | 29.50M | Aug 10, 2022 |
| FY2021 | Mar 31, 2020 | 29.35M | Jun 10, 2021 |
| FY2020 | Mar 31, 2019 | 29.23M | Jun 11, 2020 |
| FY2019 | Mar 31, 2018 | 28.82M | Jun 27, 2019 |
| FY2018 | Mar 31, 2017 | 28.82M | Jun 28, 2018 |
| FY2017 | Mar 31, 2016 | 27.32M | Jun 29, 2017 |